AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novo Nordisk Board Member Christina Law Buys $0.8 Million in ADRs
ByAinvest
Tuesday, Aug 19, 2025 7:50 am ET1min read
Christina Law, a Novo Nordisk board member, purchased 2,350 ADRs for DKK 820,300 on August 18, as reported in a regulatory filing. Law owned 6,000 shares in Novo Nordisk at the end of last year. The transaction occurred on the New York Stock Exchange.
Christina Law, a board member of Novo Nordisk, purchased 2,350 American Depositary Receipts (ADRs) for DKK 820,300 on August 18, as reported in a regulatory filing. Law owned 6,000 shares in Novo Nordisk at the end of last year. The transaction occurred on the New York Stock Exchange [1].In response to this news, Mizuho has maintained its Neutral rating and $5.00 price target on GoodRx Holdings Inc. (NASDAQ:GDRX), currently trading at $5.15. The rating was reiterated following the company’s new collaboration with Novo Nordisk (NYSE:NVO) to expand access to branded GLP-1 medications, Ozempic and Wegovy, at $499 per month through retail channels [2].
GoodRx's stock has seen varying reactions from analysts. Mizuho views the partnership positively, noting GoodRx's historical lack of involvement in dispensing compounded GLP-1 drugs. However, Mizuho has maintained its earnings estimates and $5.00 price target until there is greater clarity on volume capture trends for the new offering [2].
Other analysts have adjusted their ratings and price targets. BofA Securities maintained its Underperform rating on GoodRx with a $3.40 price target, acknowledging the positive aspects of the company’s new product offering. UBS adjusted its price target for GoodRx from $5.25 to $4.25, while Raymond James downgraded GoodRx from Strong Buy to Outperform, reducing its price target to $5.00 from $9.00 [2].
These developments highlight significant changes and collaborations impacting GoodRx’s market position.
References:
[1] https://www.investing.com/news/analyst-ratings/mizuho-maintains-neutral-rating-on-goodrx-stock-amid-novo-nordisk-partnership-93CH-4198235
[2] https://www.investing.com/news/analyst-ratings/mizuho-maintains-neutral-rating-on-goodrx-stock-amid-novo-nordisk-partnership-93CH-4198235
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet